Table 2

Distribution of class II HLA alleles among cervical carcinoma cases and HPV-positive and HPV-negative controls [n (%)]

AlleleCases (n = 55)aControlsDRB1-DQB1 haplotypeCases (n = 55)aControls
HPV + (n = 83)aHPV − (n = 107)aHPV + (n = 83)aHPV − (n = 107)a
DRB1
01011 (0.9%)0 (0.0%)2 (0.9%)0101-05011 (0.9%)0 (0.0%)2 (0.9%)
01023 (2.7%)5 (3.0%)4 (1.9%)0102-05013 (2.7%)5 (3.0%)4 (1.9%)
03016 (5.4%)10 (6.0%)8 (3.8%)0301-0201/26 (5.5%)9 (5.4%)8 (3.7%)
03025 (4.5%)13 (7.8%)16 (7.5%)0301-02030 (0.0%)1 (0.6%)0 (0.0%)
04010 (0.0%)1 (0.6%)1 (0.5%)0301-05010 (0.0%)1 (0.6%)0 (0.0%)
04030 (0.0%)1 (0.6%)2 (0.9%)0302-04025 (4.5%)13 (7.8%)15 (7.0%)
04052 (1.8%)5 (3.0%)9 (4.2%)0302-05010 (0.0%)0 (0.0%)1 (0.5%)
070110 (9.1%)8 (4.8%)5 (2.4%)0401-03010 (0.0%)1 (0.6%)0 (0.0%)
08045 (4.5%)7 (4.2%)8 (3.8%)0401-03020 (0.0%)0 (0.0%)1 (0.5%)
08062 (1.8%)3 (1.8%)1 (0.5%)0403-03020 (0.0%)1 (0.6%)1 (0.5%)
090110 (9.1%)6 (3.6%)8 (3.8%)0405-0201/22 (1.8%)1 (0.6%)2 (0.9%)
100117 (15.5%)17 (10.2%)28 (13.2%)0405-03020 (0.0%)4 (2.4%)0 (0.0%)
110112 (10.9%)22 (13.3%)13 (6.1%)0701-0201/210 (9.1%)8 (4.8%)4 (1.9%)
11025 (4.5%)6 (3.6%)24 (11.3%)0701-02030 (0.0%)0 (0.0%)1 (0.5%)
11041 (0.9%)1 (0.6%)0 (0.0%)0804-03015 (4.5%)7 (4.2%)7 (3.3%)
12010 (0.0%)0 (0.0%)3 (1.4%)0804-06040 (0.0%)0 (0.0%)1 (0.5%)
12020 (0.0%)0 (0.0%)1 (0.5%)0806-06022 (1.8%)3 (1.8%)1 (0.5%)
13013 (2.7%)6 (3.6%)17 (8.0%)0901-02019 (8.2%)6 (3.6%)7 (3.3%)
13025 (4.5%)16 (9.6%)19 (9.0%)0901-02031 (0.9%)0 (0.0%)1 (0.5%)
13034 (3.6%)7 (4.2%)4 (1.9%)1001-050117 (15.5%)17 (10.2%)28 (13.1%)
130411 (10.0%)26 (15.7%)30 (14.2%)1101-02030 (0.0%)0 (0.0%)1 (0.5%)
13221 (0.9%)3 (1.8%)3 (1.4%)1101-030111 (10.0%)12 (7.2%)6 (2.8%)
14012 (1.8%)0 (0.0%)1 (0.5%)1101-05011 (0.9%)3 (1.8%)5 (2.3%)
15033 (2.7%)0 (0.0%)1 (0.5%)1101-05020 (0.0%)1 (0.6%)0 (0.0%)
16022 (1.8%)3 (1.8%)4 (1.9%)1101-06020 (0.0%)5 (3.0%)0 (0.0%)
DQB1 1101-06040 (0.0%)1 (0.6%)1 (0.5%)
0201/227 (24.5%)26 (15.7%)24 (11.2%)1102-03015 (4.5%)5 (3.0%)23 (10.7%)
02031 (0.9%)1 (0.6%)3 (1.4%)1102-03020 (0.0%)1 (0.6%)0 (0.0%)
030137 (33.6%)57 (34.3%)71 (33.2%)1104-03011 (0.9%)1 (0.6%)0 (0.0%)
03020 (0.0%)8 (4.8%)11 (5.1%)1201-03010 (0.0%)0 (0.0%)3 (1.4%)
04025 (4.5%)13 (7.8%)15 (7.0%)1202-06020 (0.0%)0 (0.0%)1 (0.5%)
050125 (22.7%)36 (21.7%)51 (23.8%)1301-0201/20 (0.0%)0 (0.0%)2 (0.9%)
05022 (1.8%)5 (3.0%)4 (1.9%)1301-13020 (0.0%)1 (0.6%)1 (0.5%)
05032 (1.8%)0 (0.0%)1 (0.5%)1301-06020 (0.0%)1 (0.6%)0 (0.0%)
06024 (3.6%)9 (5.4%)7 (3.3%)1301-06033 (2.7%)3 (1.8%)14 (6.5%)
06034 (3.6%)5 (3.0%)18 (8.4%)1302-0201/20 (0.0%)1 (0.6%)0 (0.0%)
06042 (1.8%)3 (1.8%)8 (3.7%)1302-05012 (1.8%)10 (6.0%)13 (6.1%)
06050 (0.0%)1 (0.6%)0 (0.0%)1302-05020 (0.0%)1 (0.6%)0 (0.0%)
06091 (0.9%)2 (1.2%)1 (0.5%)1302-06042 (1.8%)1 (0.6%)5 (2.3%)
1302-06050 (0.0%)1 (0.6%)0 (0.0%)
1302-06091 (0.9%)2 (1.2%)1 (0.5%)
1303-0201/20 (0.0%)1 (0.6%)1 (0.5%)
1303-03014 (3.6%)6 (3.6%)3 (1.4%)
1304-030111 (10.0%)25 (15.1%)29 (13.6%)
1304-03020 (0.0%)1 (0.6%)0 (0.0%)
1304-06040 (0.0%)0 (0.0%)1 (0.5%)
1322-06031 (0.9%)2 (1.2%)3 (1.4%)
1322-06040 (0.0%)1 (0.6%)0 (0.0%)
1401-05032 (1.8%)0 (0.0%)1 (0.5%)
1503-03011 (0.9%)0 (0.0%)0 (0.0%)
1503-06022 (1.8%)0 (0.0%)1 (0.5%)
1602-05022 (1.8%)3 (1.8%)4 (1.9%)
  • a Each subject contributes two alleles (haplotypes) to the analysis, thus, the total number of alleles (haplotypes) in each Column is twice the number of subjects. One HPV negative control sample could not be HLA-typed for the DRB1 locus (it was known to be positive for alleles in the DRB1*03, *11, or *13 groups) and was excluded from the analyses.